Immune-peptide terms and care questions
Withdrawn: what was taken back?
- Withdrawn request
- A group asked FDA to consider allowing an ingredient in medicines made to order, then took that request back.
FDA (Food and Drug Administration) reviews medicines for US approval.
Did the FDA remove the concerns?
The page marked April 22, 2026 still prints potential safety concerns next to the withdrawn entries.
Do not read the table heading as an all-clear.
Did this give pharmacies permission to use it?
No. Taking back a request does not grant approval for making medicine with the ingredient. It does not put the ingredient under FDA’s temporary policy for certain ingredients awaiting a decision.
Neither thymosin alpha-1 nor LL-37 is covered by that policy in the record checked here.
US status as of September 26, 2026.
That policy says FDA does not plan to act against a pharmacy for using certain ingredients while it decides whether to allow them. The pharmacy must meet the policy’s conditions. This is not approval or a statement that using the ingredient is lawful.
Ask which rule allows a pharmacy to make the exact medicine you were offered.
Would a committee vote change the rules?
An FDA advisory committee gives advice; its vote does not itself change the ingredient list in law.
US status as of September 26, 2026.
Check the rule or product approval that the claim points to. A headline about a meeting cannot stand in for that record.